Neuropathy and Related Findings in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To describe the development and progression of neuropathy and related findings among patients with type 1 diabetes who participated in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. RESEARCH DESIGN AND METHODS: The main diabetic peripheral neuropathy (DPN) outcome was assessed using clinical symptoms, signs, and nerve conduction study results during DCCT and repeated in EDIC year 13/14. Cardiovascular autonomic neuropathy (CAN) was assessed by R-R response to paced breathing, Valsalva ratio, and blood pressure response to standing during DCCT and in EDIC years 13/14 and 16/17. Additionally, symptoms reflecting neuropathic pain and autonomic function (including hypoglycemia awareness) were collected yearly in EDIC using standardized questionnaires; peripheral neuropathy was also assessed annually using the Michigan Neuropathy Screening Instrument. Assessments of genitourinary function were collected at EDIC year 10. RESULTS: Intensive therapy during the DCCT significantly reduced the risk of DPN and CAN at DCCT closeout (64% and 45%, respectively, P < 0.01). The prevalence and incidence of DPN and CAN remained significantly lower in the DCCT intensive therapy group compared with the DCCT conventional therapy group through EDIC year 13/14. CONCLUSIONS: The persistent effects of prior intensive therapy on neuropathy measures through 14 years of EDIC largely mirror those observed for other diabetes complications. DCCT/EDIC provides important information on the influence of glycemic control, and the clinical course of diabetic neuropathy, and, most important, on how to prevent neuropathy in type 1 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A combination of typical symptomatology and symmetrical distal sensory loss, or typical signs in the absence of symptoms, in a person with DM is highly suggestive of DPN and may not require additional evaluations or referral.547,565–567”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [565]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The diagnosis of DPN is principally a clinical one.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [565]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The Diabetes Control and Complications Trial (DCCT) and its observational follow-up study, Epidemiology of Diabetes Interventions and Complications (EDIC), conclusively demonstrated that intensive glucose control applied early in the course of type 1 diabetes (T1D), significantly reduces the risk of developing CAN [2–4].”
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Electrophysiological testing or referral to a neurologist is rarely needed for diagnosis, except in situations where the clinical features are atypical, the diagnosis is unclear, and a different etiology is suspected.547,554,565”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [565]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Tesfaye, S., Boulton, A. J. M., Dyck, P. J., Freeman, R., Horowitz, M., Kempler, P., Lauria, G., Malik, R. A., Spallone, V., Vinik, A., et al. (2010) · Diabetes Care · doi:10.2337/dc10-1303 · Cited by 2,690
The global burden of diabetic foot disease
Boulton, A. J., Vileikyte, L., Ragnarson-Tennvall, G., & Apelqvist, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67698-2 · Cited by 2,566 · cited 1×
“Painful symptoms are frequently refractory to treatment, and loss of protective sensation heightens the risk for foot ulceration and lowerextremity amputations (19,20).”
BackgroundVascular risk factors and diabetic neuropathy
Tesfaye, S., Chaturvedi, N., Eaton, S. E. M., Ward, J. D., Manes, C., Ionescu-Tirgoviste, C., Witte, D. R., & Fuller, J. H. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa032782 · Cited by 1,323
Feldman, E. L., Stevens, M. J., Thomas, P. K., Brown, M. B., Canal, N., & Greene, D. A. (1994) · Diabetes Care · doi:10.2337/diacare.17.11.1281 · Cited by 1,293
Spallone, V., Ziegler, D., Freeman, R., Bernardi, L., Frontoni, S., Pop‐Busui, R., Stevens, M., Kempler, P., Hilsted, J., Tesfaye, S., et al. (2011) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1239 · Cited by 957
Self-citationEffect of intensive therapy on the microvascular complications of type 1 diabetes mellitus
The Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.287.19.2563 · Cited by 941
Maser, R. E., Mitchell, B. D., Vinik, A. I., & Freeman, R. (2003) · Diabetes Care · doi:10.2337/diacare.26.6.1895 · Cited by 578 · cited 1×
“Yet, CAN is an independent predictor of mortality (21,22), possibly by promoting life-threatening arrhythmias and sudden death in response to a variety of insults including drug side effects, hypoglycemia, hypokalemia, hypotension, or ischemia (23).”
Background
Cited by
Items 101–200 of 572
Evans, M., Morgan, A. R., Patel, D., Dhatariya, K., Greenwood, S. A., Newland‐Jones, P., Hicks, D., Yousef, Z. R., Moore, J., Kelly, B., et al. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00963-2 · Cited by 57
Update on the Management of Diabetic Neuropathy
Ang, L., Cowdin, N., Mizokami-Stout, K., & Pop-Busui, R. (2018) · Diabetes Spectrum · doi:10.2337/ds18-0036 · Cited by 55
“There is also robust evidence for CAN prevention with intensive glucose control designed to achieve near-normal glycemia in type 1 diabetes (11), as documented by a 45% reduction in the risk of incident CAN, assessed with highly reproducible and sensitive tests in a large sample during the Diabetes Control and Complic…”
BackgroundSelf-citationCalles-Escandón, J., Koch, K. L., Hasler, W. L., Van Natta, M. L., Pasricha, P. J., Tonascia, J., Parkman, H. P., Hamilton, F., Herman, W. H., Basina, M., et al. (2018) · PLOS ONE · doi:10.1371/journal.pone.0194759 · Cited by 55
He, L., Wang, H., Gu, C., He, X., Zhao, L., & Tong, X. (2016) · Journal of Diabetes Research · doi:10.1155/2016/1081657 · Cited by 54
“Neuropathic pain is a typical clinical symptom, which can reduce the quality of life and limit patients’ mobility [22], and drugs have only been approved specifically for the relief the neuropathic pain [23, 24], not to reverse neuronal loss [25, 26].”
BackgroundEffect of interstitial fluid pH on transdermal glucose extraction by reverse iontophoresis
Zhu, W., Yu, H., Pu, Z., Guo, Z., Zheng, H., Li, C., Zhang, X., Li, J., & Li, D. (2023) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2023.115406 · Cited by 53
Pop‐Busui, R., Backlund, J. C., Bebu, I., Braffett, B. H., Lorenzi, G., White, N. H., Lachin, J. M., Soliman, E. Z., & DCCT/EDIC Research Group (2022) · Journal of Diabetes Investigation · doi:10.1111/jdi.13635 · Cited by 52
Self-citationPathways in the Diagnosis and Management of Diabetic Polyneuropathy
Kaku, M. C., Vinik, A. I., & Simpson, D. M. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0609-2 · Cited by 52
2018 Guidelines on the management of diabetic patients. A position of Diabetes Poland
Diabetology, C. (2018) · Clinical Diabetology · doi:10.5603/dk.2018.0001 · Cited by 52
Cardoso, C. R. L., Moran, C. B. M., Marinho, F. D. S., Ferreira, M. T., & Salles, G. F. (2015) · Diabetologia · doi:10.1007/s00125-015-3658-9 · Cited by 52
Update on Estimation of Kidney Function in Diabetic Kidney Disease
Bjornstad, P., Cherney, D. Z. I., & Maahs, D. M. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0633-2 · Cited by 52
An, X., Liao, G., Chen, Y., Luo, A., Liu, J., Yuan, Y., Li, L., Yang, L., Wang, H., Liu, F., et al. (2019) · Stem Cell Research & Therapy · doi:10.1186/s13287-019-1401-z · Cited by 50
Zhao, W., Zeng, H., Zhang, X., Liu, F., Pan, J., Zhao, J., Zhao, J., Li, L., Bao, Y., Liu, F., et al. (2016) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2016.01.018 · Cited by 49
An update on the diagnosis and treatment of diabetic somatic and autonomic neuropathy
Azmi, S., Petropoulos, I. N., Ferdousi, M., Ponirakis, G., Alam, U., & Malik, R. A. (2019) · F1000Research · doi:10.12688/f1000research.17118.1 · Cited by 49
Rajan, S., Campagnolo, M., Callaghan, B. C., & Gibbons, C. H. (2018) · Clinical Autonomic Research · doi:10.1007/s10286-018-0540-0 · Cited by 47
Diabetic neuropathy: Past, present, and future.
Aldave, J. E. Q., Durand‐Vásquez, M. D. C., Osorio, E. R. G., Suárez-Rojas, J., Roseboom, P. J., Alcalá‐Mendoza, R. M., Arroyo, J., Zavaleta‐Gutiérrez, F. E., Urteaga, L. A. C., & Concepción‐Zavaleta, M. J. (2023) · PubMed Central · doi:10.22088/cjim.14.2.153 · Cited by 47
Perkins, B. A., Bril, V., & Izenberg, A. (2015) · Seminars in Neurology · doi:10.1055/s-0035-1558972 · Cited by 46
Hu, Y., Liu, F., Shen, J., Zeng, H., Li, L., Zhao, J., Zhao, J., Lu, F., & Jia, W. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0381 · Cited by 46
Diabetic nephropathy: What does the future hold?
Montero, R., Covic, A. C., Gnudi, L., & Goldsmith, D. J. A. (2015) · International Urology and Nephrology · doi:10.1007/s11255-015-1121-y · Cited by 45
Clustering of microvascular complications in Type 1 diabetes mellitus
Bjerg, L., Hulmán, Á., Charles, M., Jørgensen, M. E., & Witte, D. R. (2018) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2018.01.011 · Cited by 45
Stubbs, E. B., Fisher, M. A., Miller, C. M., Jelinek, C. S., Butler, J., McBurney, C., & Collins, E. G. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.00051 · Cited by 45
Simpson, R. W., & Wlodarczyk, J. H. (2016) · Diabetes Care · doi:10.2337/dc16-0123 · Cited by 45
Williams, K., Burns, K. A., Constantino, M., Shackel, N. A., Prakoso, E., Wong, J., Wu, T., George, J., McCaughan, G. W., & Twigg, S. M. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.06.015 · Cited by 45
Bilir, S. P., Hellmund, R., Wehler, B., Li, H., Munakata, J., & Lamotte, M. (2018) · European Endocrinology · doi:10.17925/ee.2018.14.2.73 · Cited by 34
Diabetes and Peripheral Nerve Disease
Zilliox, L. A. (2021) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2020.12.001 · Cited by 42
Bhandari, R., Sharma, A., & Kuhad, A. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.790747 · Cited by 41
“The pervasiveness of DPN in adults increased to 30% from 6% in type 1 diabetic patients as per the study conducted by Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) (24).”
MethodDiabetic Kidney Disease in Adolescents With Type 2 Diabetes: New Insights and Potential Therapies
Bjornstad, P., Cherney, D. Z. I., Maahs, D. M., & Nadeau, K. J. (2016) · Current Diabetes Reports · doi:10.1007/s11892-015-0708-0 · Cited by 41
Effects of pomegranate seed oil on metabolic state of patients with Type 2 diabetes mellitus
Mirmiran, P., Faghihimani, Z., Sohrab, G., Iraj, B., & Faghihimani, E. (2016) · International Journal of Preventive Medicine · doi:10.4103/2008-7802.194883 · Cited by 40
Monnier, V. M., Sell, D. R., Gao, X., GENUTH, S. M., Lachin, J. M., & Bebu, I. (2022) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002667 · Cited by 40
Bjerg, L., Hulman, A., Carstensen, B., Charles, M., Witte, D. R., & Jørgensen, M. E. (2019) · Diabetologia · doi:10.1007/s00125-019-4812-6 · Cited by 39
Ambulatory screening of diabetic neuropathy and predictors of its severity in outpatient settings
Qureshi, M. S., Iqbal, M., Zahoor, S., Ali, J., & Javed, M. U. (2016) · Journal of Endocrinological Investigation · doi:10.1007/s40618-016-0581-y · Cited by 39
“DCCT/EURODIAB [24] also reported that HbA1c was an important determinant of neuropathy incidence.”
BackgroundStandards of Care in Diabetes. The position of Diabetes Poland – 2025
Araszkiewicz, A., Borys, S., Broncel, M., Budzynski, A. Z., Cyganek, K., Cypryk, K., CYRANKA, K. M., Czupryniak, L., Dąbrowski, M., Dzida, G. J., et al. (2025) · Current Topics in Diabetes · doi:10.5114/ctd/203685 · Cited by 38
Marchettini, P., Wilhelm, S., Petto, H., Tesfaye, S. H., Tölle, T. R., Bouhassira, D., Freynhagen, R., Cruccu, G., Lledó, A., Choy, E., et al. (2015) · European Journal of Pain · doi:10.1002/ejp.763 · Cited by 38
“We also concede that presence of depression was not formally tested using standard diagnostic tools such as the HADS (Hamilton, 1960, 1967) or the Montgomery Asberg Depression Rating Scale (Montgomery and Asberg, 1979).”
MethodVantyghem, M., Quintin, D., Caiazzo, R. J., Leroy, C., Raverdy, V., Cassim, F., Glowacki, F., Hübert, T., Gmyr, V., Noël, C., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0320 · Cited by 38
Diabetic Peripheral Neuropathy: Epidemiology, Physiopathology, Diagnosis and Treatment
Akter, N. (2019) · Delta Medical College Journal · doi:10.3329/dmcj.v7i1.40619 · Cited by 37
Diabetes Mellitus and Diabetic Peripheral Neuropathy
Bruschi, L. K. M., da Rocha, D. A., Filho, E. L. G., Barboza, N. D. M. P., Frisanco, P. A. B., Callegaro, R. M., de Sá, L. B. P. C., & Arbex, A. K. (2017) · Open Journal of Endocrine and Metabolic Diseases · doi:10.4236/ojemd.2017.71002 · Cited by 36
Didangelos, T., Τζιόμαλος, Κ., Margaritidis, C., Kontoninas, Z., Stergiou, I., Tsotoulidis, S., Karlafti, E., Mourouglakis, A., & Hatzitolios, A. I. (2017) · Journal of Diabetes Research · doi:10.1155/2017/6719239 · Cited by 36
Aspectos celulares y moleculares de la nefropatía diabética, rol del VEGF-A
Carranza, K., Verón, D., Cercado, A. G., Bautista, N., Pozo, W., Tufró, A., & Verón, D. (2015) · Nefrología · doi:10.1016/j.nefro.2015.05.013 · Cited by 36
Hajaš, G., Kissova, V., & Tirpáková, A. (2016) · Pediatric Diabetes · doi:10.1111/pedi.12382 · Cited by 36
“However, DCCT/EDIC also revealed that current strategies for optimising glucose control for most patients with type 1 diabetes are insufficient to completely prevent or delay the development of DPN and CAN (25).”
BackgroundInfluentialCan Resistance Exercise Be a Tool for Healthy Aging in Post-Menopausal Women with Type 1 Diabetes?
Momeni, Z., Logan, J. E., Sigal, R. J., & Yardley, J. E. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18168716 · Cited by 35
“Frequent hyperglycemia, on the other hand, can lead to increased HbA1c, and a subsequent increase in the risk of retinopathy and nephropathy [134,135], neuropathy [136], and all-cause morbidity and mortality from CVD and CHD [137].”
BackgroundMarigliano, M., Eckert, A. J., Guness, P. K., Herbst, A., Smart, C. E., Witsch, M., Maffeis, C., & SWEET Study Group (2021) · Pediatric Diabetes · doi:10.1111/pedi.13274 · Cited by 37
Cardiac autonomic function in children with type 1 diabetes
Metwalley, K. A., Hamed, S. A., & Farghaly, H. S. (2018) · European Journal of Pediatrics · doi:10.1007/s00431-018-3122-1 · Cited by 35
“hypertension, hypercholesterolemia/dyslipidemia) [19].”
Shao, B., Zelnick, L. R., Wimberger, J., Himmelfarb, J., Brunzell, J. D., Davidson, W. S., Snell‐Bergeon, J. K., Bornfeldt, K., de Boer, I. H., & Heinecke, J. W. (2019) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.119.312556 · Cited by 35
Gogan, A., Potre, O., Avram, V. F., Andor, M., Căruntu, F. R., & Timar, B. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14030671 · Cited by 35
“At least 10 to 15% of patients with T2D who are newly diagnosed may have DSPN, and after ten years, the prevalence rises to 50% [14,15].”
da Rosa, L. C. G. F., Zajdenverg, L., Souto, D. L., Dantas, J. R., Pinto, M. V., de Salles, G. F. D. C. M., & Rodacki, M. (2019) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2019.05.022 · Cited by 34
Skin autofluorescence and peripheral neuropathy four years later in type 1 diabetes
Rajaobelina, K., Farges, B., Nov, S., Maury, E., Cephise-Velayoudom, F. L., Gin, H., Helmer, C., & Rigalleau, V. (2016) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2832 · Cited by 34
Effects of islet transplantation on microvascular and macrovascular complications in type 1 diabetes
Reid, L. J., Baxter, F., & Forbes, S. (2021) · Diabetic Medicine · doi:10.1111/dme.14570 · Cited by 34
Uncovering sensory axonal dysfunction in asymptomatic type 2 diabetic neuropathy
Sung, J., Tani, J., Chang, T., & Lin, C. S.-Y. (2017) · PLoS ONE · doi:10.1371/journal.pone.0171223 · Cited by 33
Sleep disturbances in diabetic peripheral neuropathy patients: a clinical and polysomnographic study
Bahnasy, W. S., El-Heneedy, Y. A. E., El-Seidy, E. A. S., Labib, N. A. A., & Ibrahim, I. S. E. (2018) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-018-0024-0 · Cited by 33
Diabetic neuropathy in children and youth: New and emerging risk factors
Akıncı, G., Savelieff, M. G., Gallagher, G., Callaghan, B. C., & Feldman, E. L. (2020) · Pediatric Diabetes · doi:10.1111/pedi.13153 · Cited by 33
“Although both standard and intensive glycemic control groups had comparable HbA1c levels (around 8%) one year after treatment initiation as per EDIC protocol, subjects within the former intensive group had lower DN incidence at year 8 and years 13–14.(202,203) Mean HbA1c was recently identified as the most significant…”
BackgroundTurner, K. M., Delman, A. M., Donovan, E. C., Brunner, J., Wahab, S. A., Dai, Y., Choe, K. A., Smith, M. T., Patel, S. H., Ahmad, S. A., et al. (2022) · HPB · doi:10.1016/j.hpb.2022.07.001 · Cited by 33
Standards of Care in Diabetes. The position of Diabetes Poland – 2024
Araszkiewicz, A., Bandurska-Stankiewicz, E. M., Borys, S., Broncel, M., Budzynski, A. Z., Cyganek, K., Cypryk, K., CYRANKA, K. M., Czupryniak, L., Dzida, G. J., et al. (2024) · Current Topics in Diabetes · doi:10.5114/ctd/183052 · Cited by 33
Plantar fasciitis in patients with type 1 and type 2 diabetes: A contemporary cohort study
Priesand, S., Schmidt, B. M., Ang, L. P., Wrobel, J. S., Munson, M. E., Ye, W., & Pop‐Busui, R. (2019) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2019.06.004 · Cited by 32
Self-citationPrevalence and Determinants of Painful and Painless Neuropathy in Type 1 Diabetes Mellitus
Barbosa, M., Saavedra, A., Oliveira, S. C., Reis, L. D. D., Rodrigues, F., Severo, M., Sittl, R., Maier, C., & Carvalho, D. M. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00402 · Cited by 32
“Worldwide, the incidence and prevalence of DSPN vary greatly, but evidence from several large observational cohorts (6) such as the Diabetes Control and Complications Trial (DCCT) and Epidemiology of Diabetes Interventions and Complications (EDIC) (7) suggest that DSPN occurs in at least 20% of people with type 1 DM (…”
BackgroundState-of-the-art pharmacotherapy for diabetic neuropathy
Azmi, S., Alam, U., Burgess, J., & Malik, R. A. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1812578 · Cited by 32
A potent weighted risk model for evaluating the occurrence and severity of diabetic foot ulcers
Shi, L., Wei, H., Zhang, T., Li, Z., Chi, X., Liu, D., Chang, D., Zhang, Y., Wang, X., & Zhao, Q. (2021) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-021-00711-x · Cited by 32
“Abbreviations AUC : Area under curve; BMI: Body mass index; CI: Confidence interval; DFU: Diabetic foot ulcer; DPN: Diabetic peripheral neuropathy; DR: Diabetic retinopathy; eGFR: Estimated glomerular filtration rate; HbA1c: Hemoglobin A1c; NPDR: Non-proliferative diabetic retinopathy; PDR: Proliferative diabetic reti…”
BackgroundHu, Y., Hu, Z., Tang, W., Liu, W., Wu, X., & Pan, C. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s354872 · Cited by 32
Cefalu, W. T., & Ratner, R. E. (2013) · Diabetes Care · doi:10.2337/dc13-2369 · Cited by 31
Elafros, M. A., & Callaghan, B. C. (2023) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001291 · Cited by 31
Peripheral sensory neuropathy in type 2 diabetes patients: A case control study in Accra, Ghana
Yeboah, K., Puplampu, P., Boima, V., Antwi, D. A., Gyan, B., & Amoah, A. G. B. (2016) · Journal of Clinical & Translational Endocrinology · doi:10.1016/j.jcte.2016.07.001 · Cited by 31
Kumar, N., Pop‐Busui, R., Musch, D. C., Reed, D. M., Momont, A. C., Hussain, M., Raval, N., Moroi, S. E., & Shtein, R. M. (2018) · Cornea · doi:10.1097/ico.0000000000001668 · Cited by 30
Self-citationDiabetic Polyneuropathy – Advances in Diagnosis and Intervention Strategies
Tesfaye, S. H., & SLOAN, G. P. (2020) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2020.16.1.15 · Cited by 30
Bebu, I., Braffett, B. H., Schade, D., Sivitz, W., Malone, J. I., Pop-Busui, R., Lorenzi, G. M., Lee, P., Trapani, V. R., Wallia, A., et al. (2020) · Diabetes Care · doi:10.2337/dc20-0226 · Cited by 29
Self-citationNiu, Y., Li, J., Peng, R., Zhao, X., Wu, J., & Tang, Q. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3162 · Cited by 29
“We included T2DM patients with and without DPN. DPN was diagnosed and categorized according to the standard of Martin CL, et al.13 The exclusion criteria for the study was as follows: (a) patients with nondiabetic‐related neuropathy, (b) patients with severe liver or renal function or cardiac insufficiency, (c) patien…”
MethodShinouchi, R., Shibata, K., Hashimoto, T., Jono, S., Hasumi, K., & Nobe, K. (2020) · Pharmacology Research & Perspectives · doi:10.1002/prp2.648 · Cited by 29
“In spite of the intensive blood glucose control, the prevention of the progression of DN has not been successful.[10,55] This may be due to metabolic and enzymatic changes, and a nerve damage that occur owing to persistent hyperglycemia before exercise or use of anti-diabetes agent is started after the diagnosis of di…”
BackgroundActivation of the insulin-signaling pathway in sciatic nerve and hippocampus of type 1 diabetic rats
King, M. R., Anderson, N. J., Liu, C., Law, E. C., Cundiff, M., Mixcoatl-Zecuatl, T., & Jolivalt, C. G. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.06.060 · Cited by 29
“…or CNS level suggests that insulin contributes to the normalization of functions such as maintenance of neuronal mitochondrial functions (Huang et al., 2003; Chowdhury et al., 2010), support of memory functions (Jolivalt et al., 2008; McNay et al., 2010) and nerve regeneration (Guo et al., 2011).”
BackgroundCheng, Z., Li, X., Xu, H., Bao, D., Mu, C., & Xing, Q. (2022) · Journal of Clinical Nursing · doi:10.1111/jocn.16371 · Cited by 28
Al-Saoudi, E., Christensen, M. M. B., Nawroth, P. P., Fleming, T. H., Hommel, E. E., Jørgensen, M. E., Fleischer, J., & Hansen, C. S. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.891442 · Cited by 28
Taboko, N. E., Assob, J. C. N., Feteh, V. F., & Choukem, S. P. (2017) · BMC Research Notes · doi:10.1186/s13104-017-2804-5 · Cited by 28
The Quest for more Research on Painful Diabetic Neuropathy
Nawroth, P. P., Bendszus, M., Pham, M., Jende, J. M. E., Heiland, S., Ries, S. R., Schumann, C., Schmelz, M., Schuh‐Hofer, S., Treede, R., et al. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.09.023 · Cited by 28
Røikjer, J., Wegeberg, A., Nikontovic, A., Brock, C., & Vestergaard, P. (2024) · Primary care diabetes · doi:10.1016/j.pcd.2024.08.006 · Cited by 27
Metabolic memory: mechanisms and implications for diabetic vasculopathies
Zhang, E., & Wu, Y. (2014) · Science China Life Sciences · doi:10.1007/s11427-014-4710-6 · Cited by 27
Urogenital Autonomic Dysfunction in Diabetes
Braffett, B. H., Wessells, H., & Sarma, A. V. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0824-5 · Cited by 27
Rasmussen, V. F., Jensen, T. S., Tankişi, H., Karlsson, P., Vestergaard, E. T., Kristensen, K., Nyengaard, J. R., & Terkelsen, A. J. (2021) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.108027 · Cited by 26
The foot in diabetes – a reminder of an ever-present risk
Craus, S., Mula, A., & Coppini, D. (2023) · Clinical Medicine · doi:10.7861/clinmed2022-0489 · Cited by 26
“34,35 The Action to”
Cost-Effectiveness of Treatment Options for Neuropathic Pain: a Systematic Review
Ruiz‐Negrón, N., Menon, J., King, J. B., Ma, J., & Bellows, B. K. (2019) · PharmacoEconomics · doi:10.1007/s40273-018-00761-6 · Cited by 26
Guo, Q., Lu, B., Guo, Z., Feng, Z., Yuan, Y., Jin, X., Zang, P., Gu, P., & Shao, J. (2020) · World Journal of Diabetes · doi:10.4239/wjd.v11.i11.489 · Cited by 26
Galiero, R., Ricciardi, D., Pafundi, P. C., Todisco, V., Tedeschi, G., Cirillo, G., & Sasso, F. C. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108856 · Cited by 26
The efficacy of PDE5 inhibitors in diabetic patients
Święcicka, A. (2022) · Andrology · doi:10.1111/andr.13328 · Cited by 25
A Machine Learning-Based Severity Prediction Tool for the Michigan Neuropathy Screening Instrument
Haque, F., Reaz, M. B. I., Chowdhury, M. E. H., Shapiai, M. I., Malik, R. A., Alhatou, M. I., Kobashi, S., Ara, I., Ali, S. H. M., Bakar, A. A. A., et al. (2023) · Diagnostics · doi:10.3390/diagnostics13020264 · Cited by 25
Stadler, M., Peric, S., Strohner-Kaestenbauer, H., Kramar, R., Kaestenbauer, T., Reitner, A., Auinger, M., Kronenberg, F., Irsigler, K., Amiel, S. A., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-2701 · Cited by 24
Advances in the management of diabetes: new devices for type 1 diabetes
Wunna, W., Tsoutsouki, J., Chowdhury, A., & Chowdhury, T. A. (2020) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2020-138016 · Cited by 25
Glycemic Variability and Diabetic Neuropathy in Young Adults With Type 1 Diabetes
Christensen, M. M. B., Hommel, E. E., Jørgensen, M. E., Fleischer, J., & Hansen, C. S. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00644 · Cited by 24
Wang, L., Chopp, M., Jia, L., Lu, X., Szalad, A., Zhang, Y., Zhang, R., & Zhang, Z. G. (2015) · Journal of Diabetes Research · doi:10.1155/2015/173656 · Cited by 24
“Our findings are consistent with studies published by others, demonstrating dissociation between hyperglycemia and peripheral neuropathy [38].”
BackgroundResultInfluentialQiao, X., Zhang, S., Zhao, W., Ye, H., Yang, Y., Zhang, Z., Miao, Q., Hu, R., Li, Y., & Lü, B. (2015) · Medicine · doi:10.1097/md.0000000000001908 · Cited by 24
Chakraborty, S., Halland, M., Burton, D., Desai, A., Neja, B., Low, P., Singer, W., Camilleri, M., Zinsmeister, A. R., & Bharucha, A. E. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01623 · Cited by 23
Association of arterial stiffness and neuropathy in diabetes: a systematic review and meta-analysis
Beros, A. L., Sluyter, J., & Scragg, R. K. R. (2023) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2022-003140 · Cited by 23
Neuropathic Pain With and Without Diabetic Peripheral Neuropathy in Type 1 Diabetes
Braffett, B. H., ghormli, L. K. E., Albers, J. W., Feldman, E. L., Herman, W. H., Gubitosi‐Klug, R., Martin, C. L., Orchard, T. J., White, N. H., Lachin, J. M., et al. (2024) · Diabetes Care · doi:10.2337/dc23-1749 · Cited by 23
Self-citationDiagnosing and managing diabetic somatic and autonomic neuropathy
Azmi, S., Ferdousi, M., Kalteniece, A., Almuhannadi, H., Al‐Mohamedi, A., Hadid, N. H., Mahmoud, S., Bhat, H., Gad, H., Khan, A., et al. (2019) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018819826890 · Cited by 23
What Is in the Field for Genetics and Epigenetics of Diabetic Neuropathy: The Role of MicroRNAs
Spallone, V., Ciccacci, C., Latini, A., & Borgiani, P. (2021) · Journal of Diabetes Research · doi:10.1155/2021/5593608 · Cited by 23
“, intensive glycemic control in type 1 diabetes that is able to prevent up to more than 60% of new cases of CAN and DPN), it is a matter of fact that for many patients (2% yearly), current strategies for optimizing glucose control are insufficient to fully prevent or delay the development of neuropathic complications…”
BackgroundDiabetes mellitus type 1 in adults
Dedov, I. I., Shestakova, M. V., Mayorov, A. Y., Шамхалова, М. Ш., Nikonova, T. V., Sukhareva, O. Y., Пекарева, Е. В., Ibragimova, L. I., Mikhina, M. S., Galstyan, G. R., et al. (2020) · Diabetes Mellitus · doi:10.14341/dm12505 · Cited by 22
Sun, X., Yang, X., Zhu, X., Yu, M., Li, X., Zhang, Y., Liu, Q., Fan, C., Zhang, M., Xu, B., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1354511 · Cited by 22
“Timely and intensive interventions can improve subclinical DPN and reduce the risk of DPN progression (5 – 7).”
BackgroundMittal, R., McKenna, K., Keith, G., McKenna, E., Lemos, J. R. N., Mittal, J., & Hirani, K. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00270 · Cited by 22
Hamasaki, H., & Hamasaki, Y. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00203 · Cited by 22
Challenges in Diabetic Micro-Complication Management: Focus on Diabetic Neuropathy
Ansari, P., Hannan, J. M. A., Azam, S., & Jakaria, M. (2021) · International Journal of Translational Medicine · doi:10.3390/ijtm1030013 · Cited by 22
Weng, X., Liao, S., Wang, F., Wang, H., & Yang, L. (2022) · Contrast Media & Molecular Imaging · doi:10.1155/2022/7665483 · Cited by 22
Chronic Pain Syndromes, Mechanisms, and Current Treatments
Sirianni, J., Ibrahim, M. M., & Patwardhan, A. M. (2015) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2015.01.004 · Cited by 22
The Application of SUDOSCAN for Screening Diabetic Peripheral Neuropathy in Chinese Population
Jin, J., Wang, W., Gu, T., Chen, W., Lü, J., Bi, Y., & Zhu, D. (2017) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0043-116673 · Cited by 22
“Each test had normative values and also calculated the autonomic neuropathy score according to previous report[13].”
MethodNorman, G. J., Fernandes, J., Nemlekar, P. M., Andrade, S. B., Lupton, L. L., & Berk, A. R. (2024) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2024.24255 · Cited by 21
Haque, F., Reaz, M. B. I., Chowdhury, M. E. H., Serkan Kiranyaz, B., Ali, S. H. M., Alhatou, M. I., Habib, R., Bakar, A. A. A., Arsad, N., & Srivastava, G. (2022) · Computational Intelligence and Neuroscience · doi:10.1155/2022/9690940 · Cited by 21
Winocour, P. H., Bain, S. C., Chowdhury, T. A., De, P., Pokrajac, A., Fogarty, D. G., Frankel, A., Banerjee, D., Wahba, M. M., & Dasgupta, I. (2018) · British Journal of Diabetes · doi:10.15277/bjd.2018.172 · Cited by 21
Metadata
- Authors
- Martin, C. L., Albers, J. W., Pop-Busui, R., & for the DCCT/EDIC Research Group
- Affiliations
- University of Michigan (US)
- Department of Internal Medicine, Division of Metabolism, Endocrinology and Diabetes, University of Michigan Medical School, Ann Arbor, MI
- Corresponding author
- Martin, Catherine L.
- ORCID
- Martin, Catherine L.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2013-12-11
- Volume
- 37
- Issue
- 1
- Pages
- 31-38
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3868000
- OpenAlex
- W2115038969
- Cited by
- 499
- References
- 30
- Citations by year
- 2026: 25 · 2025: 27 · 2024: 45 · 2023: 38 · 2022: 40 · 2021: 57 · 2020: 50 · 2019: 41 · 2018: 45 · 2017: 28 · 2016: 34 · 2015: 42 · 2014: 23 · 2013: 4
- FWCI
- 27.01
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Sanofi
- BD
- Roche Diabetes Care
- National Institutes of Health (UL1TR000041, UL1TR000114, 5u01dk094157-13, UL1TR001449)
- Abbott Diabetes Care
- National Eye Institute
- National Institute of Diabetes and Digestive and Kidney Diseases (U01DK094176, U01-DK094157, P30DK020572)
- National Institute of Neurological Disorders and Stroke
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Clinical Neurology › Peripheral Neuropathies and Disorders
- Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
- Keywords
- diabetic peripheral neuropathy, cardiac autonomic neuropathy, type 1 diabetes, tight glycemic control, neuropathy progression, neuropathic pain, hypoglycemia awareness, genitourinary function, Michigan Neuropathy Screening Instrument, DCCT/EDIC, neuropathy prevention
- MeSH terms
- Adolescent, Adult, Aged, Blood Glucose, Blood Pressure, Diabetes Mellitus, Type 1, Diabetic Neuropathies, Dose-Response Relationship, Drug, Female, Glycated Hemoglobin, Humans, Insulin, Male, Middle Aged, Neural Conduction, Peripheral Nervous System Diseases, Risk Factors, Incidence, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.